Natera surges on 29% earnings beat, oncology tests soar 55%
Genetic testing company delivers $665.5M Q4 revenue, upgrades 2026 outlook with positive cash flow
Natera shares rose sharply Tuesday after the genetic testing company reported fourth-quarter revenue that beat analyst expectations by nearly 30%, fueled by accelerating demand for its oncology diagnostics.
The San Carlos, California-based company reported revenue of $665.5 million for the quarter, surpassing the $514.8 million consensus estimate by 29.3%. The strong performance drove gross margin expansion to 66.9%, up 400 basis points from 62.9% in the same period last year, according to the company's investor relations materials.
The earnings beat marks a significant acceleration for Natera, which has transformed from a prenatal testing specialist into a major player in cancer diagnostics. Oncology test volume surged 54.7% year-over-year to 233,300 tests, underscoring the growing adoption of the company's Signatera circulating tumor DNA technology for monitoring cancer recurrence.
For the full year 2025, Natera delivered revenue of $2.31 billion, representing 35.9% growth. More notably, the company achieved $107.6 million in positive cash flow for the year, a milestone that addresses a key concern for investors in the capital-intensive diagnostic testing sector.
Looking ahead, management guided for 2026 revenue of $2.62 billion to $2.70 billion, implying approximately 25% growth. The guidance includes expectations for continued positive cash flow, suggesting the company has reached a sustainable profitability inflection point.
Natera's stock, which has been one of the healthcare sector's strongest performers with a 52-week high of $256.36, currently trades with a market valuation of $29.2 billion. The shares have gained 72% in 2025, significantly outperforming the broader biotechnology sector as investors have rewarded the company's transition from unprofitable growth to cash-generating expansion.
The company's success in oncology testing has come amid increasing competition in the molecular diagnostics market. Natera's Signatera test, which uses circulating tumor DNA to detect minimal residual disease and cancer recurrence, has gained traction with oncologists as a tool for personalized treatment monitoring. The technology's ability to provide earlier detection of recurrence than traditional imaging has positioned it as an increasingly standard component of cancer care pathways.
Analysts have largely maintained bullish positions on the stock. Of 20 analysts covering Natera, 18 rate it a buy or strong buy, with an average target price of $257.20, according to market data. Institutional investors own 96.2% of shares, reflecting conviction among large-scale healthcare investors in the company's long-term prospects.
The company's ability to expand gross margins while growing rapidly suggests improved operational efficiency and pricing power in the oncology testing market. Natera has worked to streamline its laboratory operations and scale its testing infrastructure, allowing it to process higher volumes at lower per-unit costs.
For 2026, investors will be watching whether Natera can maintain its oncology growth trajectory while continuing to improve profitability. The company's positive cash flow generation provides financial flexibility to invest in new test development and geographic expansion, particularly in European markets where Signatera adoption is still in early stages.
Natera's performance comes amid broader optimism about the molecular diagnostics sector, as advances in genomic technology enable more precise and earlier detection of cancer and other diseases. The company's focus on post-treatment monitoring, rather than just diagnostic screening, has differentiated it from competitors in the increasingly crowded liquid biopsy market.